3rd Degree Pharma

3rd Degree Pharma is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics targeting oxysterol-driven inflammatory and metabolic diseases. The company's primary focus is on the G protein-coupled receptor 183 (GPR183), also known as EBI2, which plays a critical role in immune cell migration and inflammatory responses. By modulating this pathway, 3rd Degree Pharma aims to address significant unmet needs in autoimmune and metabolic conditions. The company leverages deep expertise in GPCR pharmacology and medicinal chemistry to advance its pipeline of selective antagonists. Based in Australia, the firm is part of the growing ecosystem of biotech startups emerging from academic and research excellence in the region.